news)

NEWS

Media Contacts:

Canada

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Seqirus news releases

Seqirus news releases

COVID-19 Update
27 Mar 2020

Safeguarding our people and communities remains our top priority.

Seqirus announces Health Canada approval of first cell-based seasonal influenza vaccine
11 Dec 2019

/CNW/ - Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of age and older. Marketed as FLUCELVAX® QUAD, the vaccine offers protection against four influenza virus strains — A(H3N2), A(H1N1) and two B virus strains1.